Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Aged vs Standard Rilpivirine LA in Healthy Subjects
NCT02547870Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve. Started Aug 2015; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02547870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547870.